CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer
May 16 2022 - 4:01PM
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical
company focused on creating transformative gene-based medicines for
serious diseases, today announced the appointment of Phuong Khanh
(P.K.) Morrow, M.D., FACP, as Chief Medical Officer, effective May
23, 2022. Dr. Morrow brings more than a decade of leadership
experience in global drug development and joins CRISPR Therapeutics
to lead the Company’s global clinical development and regulatory
operations.
“P.K.’s leadership experience, deep expertise in
oncology drug development, and her track record in bringing novel
medicines to patients will be invaluable as we continue to advance
our broad portfolio of innovative gene-edited therapies,” said
Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR
Therapeutics. “She will play an integral role in shaping our
clinical development strategy, and in building and strengthening
our organization, and we look forward to her contributions as we
continue on our mission to transform medicine.”
“I am excited to join CRISPR Therapeutics’
leadership team at this important time in its growth and
evolution,” said Dr. Phuong Khanh (P.K.) Morrow. “The potential of
the Company’s pre-eminent gene editing platform combined with the
broad pipeline creates a tremendous opportunity to bring several
novel and potentially transformative therapies to patients in
need.”
During her biopharmaceutical career, Dr. Morrow
has demonstrated outstanding leadership in bringing novel medicines
through all phases of clinical development and global regulatory
approval. Specializing in the therapeutic areas of oncology and
hematology, she has been responsible for end-to-end development of
numerous drug candidates and for the implementation of strategic
partnerships with academic institutions, key opinion leaders and
biopharmaceutical co-collaborators to facilitate the successful
execution of clinical trials. Dr. Morrow most recently served as
Vice President and Global Therapeutic Area Head of Hematology, GI
Oncology, GU Oncology, and Bone at Amgen, where she was responsible
for guiding and accelerating late development activities addressing
marketed hematology programs, Blincyto® and Kyprolis®, and guiding
the late development strategy for programs that focus upon FLT3 and
MCL-1. She also led the medical launch activities for Imlygic®,
Kyprolis®, Neulasta Onpro™ and Blincyto®; served as the Global
Product General Manager for three early-stage oncology molecules
focused upon MCL-1 and KRAS G12C; and led a cross-functional team
in the development and registration of Neulasta® Onpro™ and the
successful submission of the Neupogen® and Neulasta® Acute
Radiation Syndrome (ARS) sBLAs, leading to the regulatory approval
of both products for the ARS indication. In addition, Dr. Morrow
was appointed by the U.S. Food and Drug Administration (FDA) to be
the industry representative to the Oncology Drug Advisory Committee
(ODAC) for a four-year term, ending in 2019.
Previously, Dr. Morrow was Assistant Professor,
Department of Breast Medical Oncology at the University of Texas MD
Anderson Cancer Center. She co-led the development of the first
multidisciplinary breast cancer survivorship clinic at MD Anderson
and served as the principal investigator of multiple drug studies.
Dr. Morrow received an M.D. from the University of Texas Medical
School at Houston, with honors, and completed her Internal Medicine
Residency at Baylor College of Medicine and Hematology/Oncology
Fellowship at the University of Texas MD Anderson Cancer Center,
where she also served as a Chief Fellow. She received a B.S. in
Pharmacy from the University of Houston.
About CRISPR TherapeuticsCRISPR
Therapeutics is a leading gene editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a
revolutionary gene editing technology that allows for precise,
directed changes to genomic DNA. CRISPR Therapeutics has
established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology,
regenerative medicine and rare diseases. To accelerate and expand
its efforts, CRISPR Therapeutics has established strategic
collaborations with leading companies including Bayer, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations based
in Cambridge, Massachusetts, and business offices in San Francisco,
California and London, United Kingdom. For more information, please
visit www.crisprtx.com.
CRISPR Therapeutics Forward-Looking
StatementThis press release may contain a number of
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including
statements made by Dr. Kulkarni and Dr. Morrow in this press
release regarding the expected benefits of Dr. Morrow’s employment,
as well as regarding CRISPR Therapeutics’ expectations about the
therapeutic value, development, and commercial potential of
CRISPR/Cas9 gene editing technologies and therapies. Without
limiting the foregoing, the words “believes,” “anticipates,”
“plans,” “expects” and similar expressions are intended to identify
forward-looking statements. You are cautioned that forward-looking
statements are inherently uncertain. Although CRISPR Therapeutics
believes that such statements are based on reasonable assumptions
within the bounds of its knowledge of its business and operations,
forward-looking statements are neither promises nor guarantees and
they are necessarily subject to a high degree of uncertainty and
risk. Actual performance and results may differ materially from
those projected or suggested in the forward-looking statements due
to various risks and uncertainties. These risks and uncertainties
include, among others: that preliminary data from any clinical
trial and initial data from a limited number of patients may not be
indicative of final or future trial results; that clinical trial
results may not be favorable or may not support registration or
further development; uncertainties about regulatory approvals to
conduct trials or to market products; that future competitive or
other market factors may adversely affect the commercial potential
for CRISPR Therapeutics’ product candidates; potential impacts due
to the coronavirus pandemic; uncertainties regarding the
intellectual property protection for CRISPR Therapeutics’
technology and intellectual property belonging to third parties,
and the outcome of proceedings (such as an interference, an
opposition or a similar proceeding) involving all or any portion of
such intellectual property; and those risks and uncertainties
described under the heading “Risk Factors” in CRISPR Therapeutics’
most recent annual report on Form 10-K, quarterly report on Form
10-Q, and in any other subsequent filings made by CRISPR
Therapeutics with the U.S. Securities and Exchange Commission,
which are available on the SEC's website at www.sec.gov. Existing
and prospective investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date they are made. CRISPR Therapeutics disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this press release, other than to the extent required
by law.
CRISPR THERAPEUTICS® word mark and design logo
are registered trademarks of CRISPR Therapeutics AG. All other
trademarks and registered trademarks are the property of their
respective owners.
Investor Contact:Susan
Kim+1-617-307-7503susan.kim@crisprtx.com
Media Contact:Rachel
Eides+1-617-315-4493rachel.eides@crisprtx.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2023 to Apr 2024